SPONSOR
Tang-Du Hospital
Total Trials
9
Recruiting
9
Phases
Phase 2, Phase 1, Phase 2
Conditions studied: Esophageal Squamous Cell CarcinomaNeuromyelitis Optica Spectrum DisorderNSCLC (Non-small Cell Lung Cancer)NSCLCCerebrovascular DiseaseLocally Advanced Cervical CancerIvonescimabNeoadjuvantLung CancerSmall Cell Lung Cancer (SCLC)
Tang-Du Hospital is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including Esophageal Squamous Cell Carcinoma, Neuromyelitis Optica Spectrum Disorder, NSCLC (Non-small Cell Lung Cancer), NSCLC.
The trial portfolio spans Phase 2, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Tang-Du Hospital
How many clinical trials has Tang-Du Hospital sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by Tang-Du Hospital, of which 9 are actively recruiting participants. These trials cover conditions including Esophageal Squamous Cell Carcinoma, Neuromyelitis Optica Spectrum Disorder, NSCLC (Non-small Cell Lung Cancer). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Tang-Du Hospital research focus on?
Tang-Du Hospital clinical trials span Esophageal Squamous Cell Carcinoma, Neuromyelitis Optica Spectrum Disorder, NSCLC (Non-small Cell Lung Cancer), NSCLC, Cerebrovascular Disease, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Tang-Du Hospital clinical trial?
To participate in a Tang-Du Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Tang-Du Hospital trials with current recruitment status updated daily.
Clinical Trials by Tang-Du Hospital
NCT07452601 Phase 2
Recruiting
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
Esophageal Squamous Cell Carcinoma
NCT05504694 Phase 1, Phase 2
Recruiting
Ofatumumab in AQP4-IgG Seropositive NMOSD
Neuromyelitis Optica Spectrum Disorder
NCT07596121 Phase 2
Recruiting
Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%
NSCLC (Non-small Cell Lung Cancer)
NCT06864624 Phase 2
Recruiting
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
NSCLC
NCT04443439
Recruiting
Assess the Risk of Cerebrovascular Disease
Cerebrovascular Disease
NCT06055738 Phase 2
Recruiting
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Locally Advanced Cervical Cancer
NCT07385001 Phase 1, Phase 2
Recruiting
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Esophageal Squamous Cell Carcinoma
NCT06644066
Recruiting
Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane
Lung Cancer
NCT06485544 Phase 2
Recruiting
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
Small Cell Lung Cancer (SCLC)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology